Small molecule inhibitors | Signal proteins inhibited | Amount used to treat cells | Cell elongation index | Preventive effect (%) |
---|---|---|---|---|
Control | N/A | N/A | 1.0 ± 0.24 | None |
MSP | none | 2.0 nM | 3.12 ± 0.47 | N.D |
CP-1 | RON | 100 μM | 1.05 ± 0.26 | 98.4% |
PD98059 | MEK1/2 | 100 μM | 1.03 ± 0.31 | 97.1% |
Wortmannin | PI-3 kinase | 50 μM | 2.9 ± 0.41 | 7.1% |
SB203580 | p38 MAP kinase | 50 μM | 3.1 ± 4.6 | 0.6% |
SP600125 | JNK1,2,3 | 5 μM | 3.07 ± 0.39 | 1.6% |
Cay10512 | NF-κB | 5 μM | 2.03 ± 0.33 | 39.4% |
S31-201 | Stat3 | 10 μM | 1.25 ± 0.34 | 59.9% |
XAV-939 | Wnt/β-catenin | 5 μM | 2.16 ± 0.32 | 30.8% |
SL0101 | RSK | 50 μM | 1.09 ± 0.27 | 97.1% |
Rapamycin | FRAP/mTOR | 100 nM | 2.69 ± 0.25 | 13.8% |
Vismodegib | Hedgehog | 1 μM | 2.04 ± 0.22 | 34.6% |
SB431542 | TGF-β1 receptor | 1 μM | 2.97 ± 0.24 | 4.8% |